Skip to content

Content transparency

  • Published:
  • Updated:
  • Editorial record: · no verified named reviewer is attached
  • Sources: 3 references listed
Authorship, review and conflicts
Named author
No verified public author identity is recorded for this page. Dog Tumor is the publisher; no veterinary authorship is implied.
Clinical review
No verified named veterinary or subject-matter reviewer is recorded for this page.
Conflicts
No page-specific conflict statement is recorded. Read the editorial standards.
Journal

Post-Treatment Surveillance in Canine Oncology: A Risk-Adapted Follow-Up Model

Clinical Review
Editorial source check: Dog Tumor Editorial Team (editorial review; not licensed veterinary review)Last reviewed: Aug 12, 2026

Summary

A structured model for tailoring rechecks to tumor behavior, treatment effects, quality of life, and the decisions that a new finding would change.

Article

Evidence-informed follow-up review. Completing surgery, radiation, or an initial chemotherapy course is not the end of oncology care. Follow-up aims to detect local recurrence, metastatic or progressive disease, a new tumor, treatment complications, and unrelated health problems while supporting quality of life. The schedule should be risk-adapted rather than copied from a generic calendar.

Define the original treatment goal

Surveillance makes sense only in relation to intent. After curative-intent local therapy, the team may monitor for recurrence and late effects. During continuous systemic treatment, examinations and laboratory tests may evaluate tolerance and disease control. After palliative treatment, comfort and function may be more informative than small imaging changes. Ask the clinician what outcome each follow-up visit is designed to detect.

Build a tumor-specific risk map

Frequency and test selection depend on diagnosis, grade, stage, primary location, margin status, typical route of spread, treatment, time since therapy, comorbidities, and owner priorities. AAHA gives broad interval examples but emphasizes tailoring. A high-grade tumor may justify closer early review than a low-grade lesion. Imaging the lungs is useful only when thoracic disease is relevant and a finding could affect care.

Three explanations for a new sign

AAHA advises considering three categories when an oncology patient develops a new problem: tumor progression, treatment toxicity, or an unrelated condition. Older dogs commonly develop arthritis, endocrine disease, dental problems, infection, and other disorders. Attributing every change to cancer can miss a treatable problem; assuming every change is unrelated can delay recognition of recurrence.

Components of a recheck

  • Interval history: appetite, weight, pain, mobility, elimination, sleep, activity, medications, and adverse events.
  • Physical examination: original site, surgical scar, relevant lymph nodes, oral cavity or other target areas, body and muscle condition, and general health.
  • Targeted measurements or photographs performed consistently when a visible lesion is being followed.
  • Laboratory monitoring chosen for the therapy and comorbidities rather than ordered automatically.
  • Imaging or sampling directed by tumor biology, previous findings, and current signs.
  • Quality-of-life and goal review, including whether the burden of monitoring still matches its value.

Response terminology

Oncology teams may use complete response, partial response, stable disease, or progressive disease. These categories rely on defined examinations or measurements and should be interpreted in the context of the original goal. Stable disease can be a useful outcome for a treatment intended to delay progression, while shrinkage may not matter if comfort worsens. Ask which lesions are being measured, by what method, and what amount of change is meaningful rather than measurement noise.

Plan for actionable findings

Before repeating a test, discuss what a concerning result would lead to: confirmatory sampling, restaging, another local treatment, systemic therapy, closer observation, or comfort-focused care. A family may reasonably decline a test if no possible result would change its decision. Conversely, early detection may preserve an option for some tumors. This is shared decision-making, not neglect.

Owner-held continuity record

Keep the original pathology, operative report, imaging, treatment dates and doses, adverse-event history, current medications and supplements, and emergency instructions in one folder. At each visit, obtain the new assessment and next due date. Clear ownership of follow-up between primary veterinarian, surgeon, and oncologist prevents missed checks and duplicated tests.

Medical disclaimer: This article is educational and cannot set a follow-up schedule or interpret a new sign for an individual dog. Follow the treating veterinary team's plan and contact them sooner for new or worsening signs. Breathing difficulty, collapse, uncontrolled bleeding, severe pain, seizures, or rapid deterioration requires emergency care.

Sources and further reading